Comparison of 18F-mFBG PETCT and 123I-mIBG Scintigraphy SPECTCT for Imaging Neuroblastoma in Children

What this Trial Is About

Researchers are evaluating the use of the radiopharmaceutical 18F-mFBG in PETCT imaging compared to the established 123I-mIBG scintigraphy SPECTCT scans for children with neuroblastoma. The study aims to assess how well 18F-mFBG can identify neuroblastoma lesions and compare its diagnostic performance with that of 123I-mIBG imaging. Participants include children with either a confirmed or presumed diagnosis of neuroblastoma based on clinical, imaging, and laboratory findings. Participants will undergo both 18F-mFBG PETCT and 123I-mIBG scintigraphy scans within a 7-day window, without receiving chemotherapy, immunotherapy, or radiotherapy between these imaging procedures. The 18F-mFBG imaging is performed using a large field of view total body PETCT scanner. Two independent teams, each consisting of a nuclear medicine physician and a pediatric radiologist, will review both imaging types while blinded to results. Discrepancies in lesion detection between the two scans will be reviewed by an expert panel. During the study, participants will have two diagnostic imaging sessions spaced closely in time. The study will evaluate lesion detection and imaging consistency through expert blinded readings. The primary outcome focuses on the ability of 18F-mFBG PET to identify neuroblastoma lesions within 60 minutes. Secondary outcomes compare the 18F-mFBG results with the clinical 123I-mIBG scans performed within seven days. The study involves informed consent and careful monitoring but does not involve treatment interventions.

18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma